Infliximab for Neurodegenerative Diseases

Infliximab for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Infliximab for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Infliximab</td>
<td>TNF-α</td>
</tr>
<tr>
<td class="label">Etanercept</td>
<td>TNF-α</td>
</tr>
<tr>
<td class="label">Adalimumab</td>
<td>TNF-α</td>
</tr>
<tr>
<td class="label">Tocilizumab</td>
<td>IL-6R</td>
</tr>
<tr>
<td class="label">Anakinra</td>
<td>IL-1β</td>
</tr>
<tr>
<td class="label">Secukinumab</td>
<td>IL-17A</td>
</tr>
</table>

Overview

Infliximab for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Infliximab for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Infliximab</td>
<td>TNF-α</td>
</tr>
<tr>
<td class="label">Etanercept</td>
<td>TNF-α</td>
</tr>
<tr>
<td class="label">Adalimumab</td>
<td>TNF-α</td>
</tr>
<tr>
<td class="label">Tocilizumab</td>
<td>IL-6R</td>
</tr>
<tr>
<td class="label">Anakinra</td>
<td>IL-1β</td>
</tr>
<tr>
<td class="label">Secukinumab</td>
<td>IL-17A</td>
</tr>
</table>

Overview

Infliximab is a chimeric monoclonal antibody that neutralizes tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine central to neuroinflammation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. It is FDA-approved for autoimmune diseases including rheumatoid arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis, and is being investigated for neuroprotection in degenerative brain diseases.

Mechanism of Action

TNF-alpha in Neurodegeneration

TNF-alpha is a key mediator of chronic neuroinflammation:

Infliximab Mechanism

Infliximab is a chimeric IgG1 monoclonal antibody that:

• Binds to both soluble and membrane-bound TNF-α with high affinity (KD ~ 10^-11 M)
• Prevents TNF-α from binding to its receptors (TNFR1/p55, TNFR2/p75)
• May induce [apoptosis](/entities/apoptosis) of TNF-α-expressing cells through antibody-dependent cellular cytotoxicity
• Does not bind to other TNF family members (lymphotoxin-α, TRAIL)

Clinical Evidence

Alzheimer's Disease (NCT02878616)

• Phase II trial sponsored by University of California, Los Angeles
• Objective: Evaluate infliximab safety and CSF biomarkers in mild cognitive impairment and AD
• Status: Completed (results published 2023)
• Key findings: Treatment was safe; trend toward reduction in CSF inflammatory markers

Parkinson's Disease

• Preclinical evidence: TNF-α levels are elevated in PD brains (substantia nigra) and CSF
• Case reports: Patients with comorbid autoimmune disease showed PD symptom improvement on TNF inhibitors
• Observational studies: Reduced PD incidence in patients on chronic TNF therapy for autoimmune conditions
• No large Phase II/III trials completed as of 2026

Amyotrophic Lateral Sclerosis (ALS)

• Rationale: Neuroinflammation is a key contributor to ALS progression
• Evidence: Elevated TNF-α in ALS patient CSF and spinal cord
• Clinical trials: No completed trials as of 2026

Multiple Sclerosis

• Paradoxical finding: TNF inhibitors can trigger demyelinating disease
• Lesson: Timing and patient selection are critical for anti-TNF therapy in CNS diseases

Dosage and Administration

In autoimmune diseases:

• Induction: 3-5 mg/kg IV at weeks 0, 2, 6
• Maintenance: Every 8 weeks thereafter

• 5 mg/kg IV infusion over 2 hours
• Pre-medication with antihistamine and acetaminophen recommended
• Monitoring required for infusion reactions

Side Effects

Common (>10%):

• Infusion reactions (headache, flushing, dyspnea)
• Headache
• Upper respiratory infections
• Nausea

• Serious infections (reactivation of TB, bacterial, fungal)
• Heart failure exacerbation
• Demyelinating disease
• Liver injury (elevated transaminases)
• Increased risk of certain malignancies (lymphoma, non-melanoma skin cancer)
• Psoriasis or psoriasiform eruptions

Comparison with Other Anti-cytokine Therapies

Research Directions

Biomarker-Driven Patient Selection

• Select patients with elevated peripheral inflammatory markers (CRP, IL-6)
• Use CSF TNF-α or sTREM2 levels as enrichment biomarkers
• Target patients with evidence of systemic inflammation

Combination Approaches

• Combine with disease-modifying therapies targeting protein aggregation
• Pair with anti-amyloid or anti-[tau](/proteins/tau) immunotherapies
• Use with antioxidants or mitochondrial protectants

Timing of Intervention

• Earlier intervention in prodromal or mild cognitive impairment stages
• Consider preventive therapy in high-risk populations
• Avoid in patients with established advanced neurodegeneration

Novel Delivery Methods

• Investigate intrathecal or convection-enhanced delivery for higher CNS penetration
• Develop TNF-neutralizing fragments with better brain access

See Also

• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [TNF-alpha Biomarker](/biomarkers/tumor-necrosis-factor-alpha-tnfa)
• [Alzheimer's Disease Treatments](/therapeutics/alzheimers-disease-treatment)
• [Parkinson's Disease Treatments](/therapeutics/parkinsons-disease-treatment)
• [Microglia in Neurodegeneration](/cell-types/microglia)
• [Blood-Brain Barrier in Neurodegeneration](/mechanisms/blood-brain-barrier)

External Links

• [Remicade Official Website](https://www.remicade.com/)
• [ClinicalTrials.gov - Infliximab Neurodegeneration](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=infliximab)
• [PubMed Search: Infliximab Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=infliximab+Alzheimer)
• [PubMed Search: Infliximab Parkinson's](https://pubmed.ncbi.nlm.nih.gov/?term=infliximab+Parkinson)

Background

The study of Infliximab For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Multi-Modal Stress Response Harmonization](/hypothesis/h-1e564178) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: NR3C1/CRH/TNFA
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;